These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7998691)

  • 1. Evaluation of topically administered tissue plasminogen activator for intraocular fibrinolysis in dogs.
    Gerding PA; Hamor RE; Ramsey DT; Vasaune S; Schaeffer DJ
    Am J Vet Res; 1994 Oct; 55(10):1368-70. PubMed ID: 7998691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of tissue plasminogen activator for intraocular fibrinolysis in dogs.
    Gerding PA; Essex-Sorlie D; Vasaune S; Yack R
    Am J Vet Res; 1992 Jun; 53(6):894-6. PubMed ID: 1626779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of intracameral injection of tissue plasminogen activator on corneal endothelium and intraocular pressure in dogs.
    Gerding PA; Essex-Sorlie D; Yack R; Vasaune S
    Am J Vet Res; 1992 Jun; 53(6):890-3. PubMed ID: 1626778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of intraocular penetration of topically administered tissue plasminogen activator in dogs.
    Gerding PA; Eurell TE
    Am J Vet Res; 1993 Jun; 54(6):836-9. PubMed ID: 8323049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical use of recombinant plasminogen activator for intraocular fibrinolysis.
    Koerner F; Boehnke M
    Ger J Ophthalmol; 1992; 1(5):354-60. PubMed ID: 1477641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Collagen shield delivery of tissue plasminogen activator: functional and pharmacokinetic studies of anterior segment delivery.
    Murray TG; Jaffe GJ; McKay BS; Han DP; Burke JM; Abrams GW
    Refract Corneal Surg; 1992; 8(1):44-8; discussion 48-53. PubMed ID: 1554639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of intraocular fibrin formation with tissue plasminogen activator after vitrectomy].
    Zhao P; Wang W
    Zhonghua Yan Ke Za Zhi; 1995 Jul; 31(4):255-8. PubMed ID: 8745515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue plasminogen activator for the treatment of postoperative intraocular fibrinous membranes following cataract surgery.
    Schmitz K; Greite JH; Bartenschlager EM
    Ger J Ophthalmol; 1995 Mar; 4(2):75-9. PubMed ID: 7795512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tissue plasminogen activator in treatment of fibrinous membranes after cataract surgery].
    Oficjalska-Młyńczak J; Marek J; Zajac-Pytrus H; Nizankowska MH; Koziorowska M
    Klin Oczna; 1996; 98(6):423-5. PubMed ID: 9340414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical tissue plasminogen activator appears ineffective for the clearance of intraocular fibrin.
    Zwaan J; Latimer WB
    Ophthalmic Surg Lasers; 1998 Jun; 29(6):476-83. PubMed ID: 9640569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sonothrombolysis for intraocular fibrin formation in an animal model.
    Yamashita T; Ohtsuka H; Arimura N; Sonoda S; Kato C; Ushimaru K; Hara N; Tachibana K; Sakamoto T
    Ultrasound Med Biol; 2009 Nov; 35(11):1845-53. PubMed ID: 19699025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
    Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of intraocular fibrinous membrane by anterior chamber injection of tissue plasminogen activator after IOL implantation].
    Xie L; Li S; Dong X; Cao J; Shi W; Guo P
    Zhonghua Yan Ke Za Zhi; 1998 Jul; 34(4):291-3. PubMed ID: 11877211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic application of tissue plasminogen activator for fibrin reaction after cataract surgery.
    Ozveren F; Eltutar K
    J Cataract Refract Surg; 2004 Aug; 30(8):1727-31. PubMed ID: 15313298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of a topical antioxidant formulation including N-acetyl carnosine on canine cataract: a preliminary study.
    Williams DL; Munday P
    Vet Ophthalmol; 2006; 9(5):311-6. PubMed ID: 16939459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinolytic activity in dogs after surgically induced trauma.
    Lanevschi A; Kramer JW; Greene SA; Meyers KM
    Am J Vet Res; 1996 Aug; 57(8):1137-40. PubMed ID: 8836363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue plasminogen activator in the management of anterior chamber fibrin formation.
    Erol N
    J Cataract Refract Surg; 2004 Nov; 30(11):2254-5; author reply 2255. PubMed ID: 15519061
    [No Abstract]   [Full Text] [Related]  

  • 18. [Changes in tissue plasminogen activator and plasminogen activator inhibitor during administration of nitroglycerine into internal thoracic artery in dogs with acute myocardial ischemia].
    Wu X; Wang CF; Sheng J; Zhu J
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2004 Sep; 16(9):527-9. PubMed ID: 15355613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical use of recombinant tissue plasminogen activator for anterior chamber fibrinolysis.
    Lin CP
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1994 Jun; 10(6):332-6. PubMed ID: 8057416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.